DDInter1635 DDInter1082
Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. Salmeterol was first described in the literature in 1988. Salmeterol's structure is similar to salbutamol's with an aralkyloxy-alkyl substitution on the amine. Salmeterol was granted FDA approval on 4 February 1994.
Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist used in the treatment of type II diabetes mellitus (T2DM). It is sold by Sanofi-Aventis under the brand name Adlyxin in the US and Lyxumia in the EU. Adlyxin recieved FDA approval July 28, 2016.
Salmeterol {u} may lead to a major life threatening interaction when taken with {v} Labetalol
Salmeterol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Salbutamol
Salmeterol {u} (Compound) resembles {v} (Compound) Hexoprenaline
Salmeterol {u} (Compound) treats {v} (Disease) asthma
Salmeterol {u} (Compound) binds {v} (Gene) ADRB2
Salmeterol {u} (Compound) upregulates {v} (Gene) EDEM1
Salmeterol {u} (Compound) is included by {v} (Pharmacologic Class) Adrenergic beta2-Agonists
Salmeterol {u} (Compound) downregulates {v} (Gene) CDC20
Salmeterol {u} (Compound) causes {v} (Side Effect) Chronic obstructive pulmonary disease
Salmeterol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Hydrocortisone
Salmeterol may lead to a major life threatening interaction when taken with Labetalol
Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol
Salmeterol (Compound) resembles Hexoprenaline (Compound)
Salmeterol (Compound) treats asthma (Disease)
Salmeterol (Compound) binds ADRB2 (Gene)
Salmeterol (Compound) upregulates EDEM1 (Gene)
Salmeterol (Compound) is included by Adrenergic beta2-Agonists (Pharmacologic Class)
Salmeterol (Compound) downregulates CDC20 (Gene)
Salmeterol (Compound) causes Chronic obstructive pulmonary disease (Side Effect)
Salmeterol may cause a minor interaction that can limit clinical effects when taken with Hydrocortisone